Location of Repository

Controlling platinum, ruthenium, and osmium reactivity for anticancer drug design

By Pieter C. A. Bruijnincx and P. J. Sadler

Abstract

The main task of the medicinal chemist is to design molecules that interact\ud specifically with derailed or degenerating processes in a diseased organism,\ud translating the available knowledge of pathobiochemical and physiological data into\ud chemically useful information and structures. Current knowledge of the biological\ud and chemical processes underlying diseases is vast and rapidly expanding. In\ud particular the unraveling of the genome in combination with, for instance, the rapid\ud development of structural biology has led to an explosion in available information and\ud identification of new targets for chemotherapy. The task of translating this wealth of\ud data into active and selective new drugs is an enormous, but realistic, challenge. It\ud requires knowledge from many different fields, including molecular biology,\ud chemistry, pharmacology, physiology, and medicine and as such requires a truly\ud interdisciplinary approach.\ud Ultimately, the goal is to design molecules that satisfy all the requirements for a\ud candidate drug to function therapeutically. Therapeutic activity can then be achieved\ud by an understanding of and control over structure and reactivity of the candidate drug\ud through molecular manipulation

Topics: RM
Publisher: Elsevier
Year: 2009
OAI identifier: oai:wrap.warwick.ac.uk:4143

Suggested articles

Preview

Citations

  1. (2006). Acta doi
  2. (2004). Cancer Res.
  3. (2008). Metals in Medicine: An Introductory Review.
  4. (2007). Organometallics doi
  5. (2008). Platinum Metals Rev. doi
  6. (2001). Protein Chem. doi
  7. (2007). Synlett doi

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.